STOCKHOLM IUPHAR MENTORING CENTRE

Site: Clinical Pharmacology, Karolinska Institutet and Karolinska University Hospital

Address: Clinical Pharmacology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden

Contact: E-mail to marja-liisa.dahl@ki.se or georgios.panagiotidis@ki.se

Affiliations:
- Dept of Laboratory Medicine and Dept of Medicine Solna, Karolinska Institutet
- Dept of Clinical Pharmacology, Karolinska University Laboratory, Karolinska University Hospital
- Center of Pharmacoepidemiology (CPE), Karolinska Institutet

Key individuals and special expertise:

- **Eleni Aklillu, Assoc prof** Drug interactions, Clinical pharmacogenetics
- **Olof Beck, Prof** Analysis of medicines and drugs of abuse, Clinical toxicology
- **Ulf Bergman, Prof MD** Drug utilization, Adverse drug reactions, Rational use of medicines (RUM)
- **Leif Bertilsson, Prof** Pharmacogenetics, Drug metabolism
- **Marja-Liisa Dahl, Prof MD** Drug Interactions, Drug Evaluation and Information, Clinical pharmacogenetics, eHealth
- **Lena Ekström, Assoc prof** Doping, Pharmacogenetics
- **Erik Eliasson, Prof MD** TDM, Clinical pharmacogenetics, Infectious diseases
- **Magnus Ericsson, PhD** Doping tests, Analysis of doping substances
- **Mia von Euler, Assoc prof MD** RUM, Neurology, Gender medicine/pharmacology
- **Lars L Gustafsson, Prof MD** RUM, CP in developing countries, eHealth and decision support
- **Anders Helander, Prof** Analysis of drugs of abuse, Clinical toxicology
- **Paul Hjemdahl, Prof MD** Drug evaluation, Cardiovascular drug therapy
- **Helle Kieler, Prof MD** Pharmacoepidemiology, Reproductive medicine
- **Pierre Lafolie, Assoc prof MD** Clinical trial methodology, Ethics, Education
- **Rickard Malmström, Assoc prof MD** RUM, Cardiovascular drug therapy
- **Georgios Panagiotidis, Assoc prof MD** Education, Phase I-II Clinical trials
- **Anton Pohanka, PhD** Analysis of medicines and drugs of abuse
- **Anders Rane, Prof MD** Pediatric Clinical Pharmacology, Doping
- **Staffan Rosenborg, MD** Nephropharmacology, Phase I-II Clinical trials
- **Carl-Olav Stiller, Ass prof, MD** Drug evaluation, Pain treatment, Psychopharmacology
- **Björn Wettermark, Assoc prof** Pharmacoepidemiology, Drug utilization
About the centre:

Clinical pharmacology in Stockholm has a long tradition in health-care services and in academia since its foundation by professor emeritus Folke Sjöqvist in the 1960s. The research is focused on studying inter- and intraindividual variability in drug response, from basic molecular mechanisms to clinical studies and epidemiology. The centre has a unit for phase I-II clinical trials and access to analytical expertise and equipment in one of the largest and most complete healthcare and R&D laboratories in Europe, including facilities for therapeutic drug monitoring, genotyping, analysis of drug of abuse and of doping agents. The research covers many pharmacotherapeutic areas such as cardiovascular, psychiatric, infectious, renal and neurological diseases, pharmacotherapy in pregnant women, children and in the elderly as well as public health. The research and education program is strengthened by its high degree of integration with the healthcare, exemplified by joint development, evaluation and research on Rational Use of Medicines, involvement in Drugs and Therapeutics Committee, structured introduction and follow-up of new medicines, development of knowledge-databases and daily patient-related consultancies provided by the laboratory and by the Karolinska Drug Information Centre. Clinical pharmacology provides weekly research seminars in English increasingly available over Internet. The clinical department has a staff of about 120, including 25 MDs, and the academic program involves about 20 senior scientists.

Research expertise:

Drug metabolism and drug-drug interactions
Pharmacokinetics and pharmacogenetics
Therapeutic drug monitoring
Analysis of drugs of abuse and clinical toxicology
Doping in sports and society
eHealth
Critical drug evaluation and work in Drug and Therapeutics Committees
Rational use of medicines
Drug safety
Clinical trials
Pharmacoepidemiology
Drug utilization
Undergraduate, postgraduate and continued education

Opportunities on offer:

Email/skype/Video conference advice on various aspects of expertise, training and education, clinical services
Seminars and other educational activities via video/internet
Potential to organize courses and training activities on demand
Research collaboration in areas of mutual interest
On-site training (if funding available)
Selected publications:


Skogh E, Sjödin I, Josefsson M, Dahl M-L. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31(1): 4-9


Schulze J, Lundmark J, Garle M, Skilving I, Ekström L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93(7): 2500-2506